These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39343635)

  • 21. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
    Tomita Y; Shimazu Y; Somasundaram A; Tanaka Y; Takata N; Ishi Y; Gadd S; Hashizume R; Angione A; Pinero G; Hambardzumyan D; Brat DJ; Hoeman CM; Becher OJ
    Glia; 2022 Sep; 70(9):1681-1698. PubMed ID: 35524725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance.
    Stegat L; Eckhardt A; Gocke A; Neyazi S; Pohl L; Schmid S; Dottermusch M; Frank S; Pinnschmidt H; Herms J; Glatzel M; Snuderl M; Schweizer L; Thomas C; Neumann J; Dorostkar MM; Schüller U; Wefers AK
    Acta Neuropathol; 2024 Sep; 148(1):40. PubMed ID: 39256213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition.
    Guo Y; Li Z; Parsels LA; Wang Z; Parsels JD; Dalvi A; The S; Hu N; Valvo VM; Doherty R; Peterson E; Wang X; Venkataraman S; Agnihotri S; Venneti S; Wahl DR; Green MD; Lawrence TS; Koschmann C; Morgan MA; Zhang Q
    bioRxiv; 2024 Aug; ():. PubMed ID: 39253432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas.
    Algranati D; Oren R; Dassa B; Fellus-Alyagor L; Plotnikov A; Barr H; Harmelin A; London N; Ron G; Furth N; Shema E
    Elife; 2024 Aug; 13():. PubMed ID: 39093942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas.
    Raab P; Banan R; Akbarian A; Esmaeilzadeh M; Samii M; Samii A; Bertalanffy H; Lehmann U; Krauss JK; Lanfermann H; Hartmann C; Brüning R
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
    Grassl N; Sahm K; Süße H; Poschke I; Bunse L; Bunse T; Boschert T; Mildenberger I; Rupp AK; Ewinger MP; Lanz LM; Denk M; Tabatabai G; Ronellenfitsch MW; Herrlinger U; Glas M; Krex D; Vajkoczy P; Wick A; Harting I; Sahm F; von Deimling A; Bendszus M; Wick W; Platten M
    Neurol Res Pract; 2023 Oct; 5(1):55. PubMed ID: 37853454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 28. Oncohistones: Hijacking the histone code.
    Sahu V; Lu C
    Annu Rev Cancer Biol; 2022 Apr; 6():293-312. PubMed ID: 36589281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffusion and perfusion imaging biomarkers of H3 K27M mutation status in diffuse midline gliomas.
    Kathrani N; Chauhan RS; Kotwal A; Kulanthaivelu K; Bhat MD; Saini J; Prasad C; Chakrabarti D; Santosh V; Uppar AM; Srinivas D
    Neuroradiology; 2022 Aug; 64(8):1519-1528. PubMed ID: 35083503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma.
    Sanders LM; Cheney A; Seninge L; van den Bout A; Chen M; Beale HC; Kephart ET; Pfeil J; Learned K; Lyle AG; Bjork I; Haussler D; Salama SR; Vaske OM
    Gigascience; 2020 Dec; 9(12):. PubMed ID: 33319914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiotherapy and radio-sensitization in H3
    Liu C; Kuang S; Wu L; Cheng Q; Gong X; Wu J; Zhang L
    CNS Neurosci Ther; 2023 Jul; 29(7):1721-1737. PubMed ID: 37157237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid biopsy in H3K27M diffuse midline glioma.
    Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
    Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
    Day CA; Hinchcliffe EH; Robinson JP
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
    Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
    Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
    Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
    Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma.
    Stafford JM; Lee CH; Voigt P; Descostes N; Saldaña-Meyer R; Yu JR; Leroy G; Oksuz O; Chapman JR; Suarez F; Modrek AS; Bayin NS; Placantonakis DG; Karajannis MA; Snuderl M; Ueberheide B; Reinberg D
    Sci Adv; 2018 Oct; 4(10):eaau5935. PubMed ID: 30402543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone H3K27M Mutation in Brain Tumors.
    El-Hashash AHK
    Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.